Hepion Pharmaceuticals Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Hepion Pharmaceuticals.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Pharmaceuticals earnings growth	17.3%
Revenue growth rate	n/a
Future return on equity	n/a
Analyst coverage	None
Last updated	n/a

Recent future growth updates

Recent updates

Additional Phase IIa Data Confirms Hepion's CRV431 As A Very Promising NASH Candidate Drug

Sep 21

Companies Like Hepion Pharmaceuticals (NASDAQ:HEPA) Are In A Position To Invest In Growth

Sep 14

Hepion Pharmaceuticals: A Promising Early-Stage Biopharma In The NASH Race

Sep 08

Treating Chronic Liver Disease - Interview With Hepion Pharmaceuticals CEO Dr. Robert Foster (Video)

May 26

What Type Of Shareholders Make Up Hepion Pharmaceuticals, Inc.'s (NASDAQ:HEPA) Share Registry?

Feb 18

Hepion Pharma cleared to advance final dosing cohort in NASH trial

Dec 29

Hepion Pharma to begin CRV431 testing in COVID-19 patients

Dec 22

Dosing underway in higher dose cohort with Hepion's CRV431 in NASH study

Dec 10

Hepion Pharma prices equity offering at $1.50

Nov 25

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Hepion Pharmaceuticals has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

NasdaqCM:HEPA - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
9/30/2024	N/A	-23	-26	-26	N/A
6/30/2024	N/A	-28	-35	-35	N/A
3/31/2024	N/A	-39	-36	-36	N/A
12/31/2023	N/A	-49	-41	-41	N/A
9/30/2023	N/A	-48	-37	-37	N/A
6/30/2023	N/A	-46	-38	-38	N/A
3/31/2023	N/A	-52	-33	-33	N/A
12/31/2022	N/A	-45	-35	-35	N/A
9/30/2022	N/A	-45	-38	-38	N/A
6/30/2022	N/A	-46	-36	-36	N/A
3/31/2022	N/A	-34	-34	-34	N/A
12/31/2021	N/A	-33	-31	-31	N/A
9/30/2021	N/A	-28	-29	-28	N/A
6/30/2021	N/A	-25	-21	-21	N/A
3/31/2021	N/A	-22	-19	-19	N/A
12/31/2020	N/A	-20	-16	-16	N/A
9/30/2020	N/A	-18	-14	-14	N/A
6/30/2020	N/A	-13	-12	-12	N/A
3/31/2020	N/A	-15	-10	-10	N/A
12/31/2019	N/A	-12	-8	-8	N/A
9/30/2019	N/A	-12	-10	-10	N/A
6/30/2019	N/A	-20	-12	-12	N/A
3/31/2019	N/A	-17	-14	-14	N/A
12/31/2018	N/A	-18	-16	-16	N/A
9/30/2018	N/A	-17	-13	-13	N/A
6/30/2018	N/A	-14	N/A	-15	N/A
3/31/2018	N/A	-8	N/A	-16	N/A
12/31/2017	N/A	-13	N/A	-18	N/A
9/30/2017	N/A	-16	N/A	-20	N/A
6/30/2017	N/A	-15	N/A	-19	N/A
3/31/2017	N/A	-22	N/A	-19	N/A
12/31/2016	N/A	-18	N/A	-18	N/A
9/30/2016	N/A	-17	N/A	-18	N/A
6/30/2016	N/A	-17	N/A	-17	N/A
3/31/2016	N/A	-17	N/A	-16	N/A
12/31/2015	N/A	-21	N/A	-15	N/A
9/30/2015	N/A	-26	N/A	-11	N/A
6/30/2015	N/A	-22	N/A	-10	N/A
3/31/2015	N/A	-12	N/A	-6	N/A
12/31/2014	N/A	-14	N/A	-4	N/A
9/30/2014	N/A	-7	N/A	-2	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if HEPA's forecast earnings growth is above the savings rate (2.8%).

Earnings vs Market: Insufficient data to determine if HEPA's earnings are forecast to grow faster than the US market

High Growth Earnings: Insufficient data to determine if HEPA's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if HEPA's revenue is forecast to grow faster than the US market.

High Growth Revenue: Insufficient data to determine if HEPA's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if HEPA's Return on Equity is forecast to be high in 3 years time

Discover growth companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/02/22 23:54
End of Day Share Price	2025/02/21 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Hepion Pharmaceuticals, Inc. is covered by 8 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
James Molloy	Alliance Global Partners
Kumaraguru Raja	Brookline Capital Markets
Kristen Kluska	Cantor Fitzgerald & Co.

Hepion Pharmaceuticals Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Price target decreased by 27% to US$30.00

Price target decreased by 46% to US$23.67

Price target decreased by 10% to US$62.67

Price target decreased to US$2.50

Price target decreased to US$4.75

Recent updates

Hepion Pharmaceuticals, Inc., Annual General Meeting, Mar 10, 2025

Hepion Pharmaceuticals Receives Written Notice from the Nasdaq Stock Market

Hepion Pharmaceuticals, Inc. has filed a Follow-on Equity Offering.

Pharma Two B Ltd. cancelled the acquisition of Hepion Pharmaceuticals, Inc. (NasdaqCM:HEPA) from Armistice Capital Master Fund Ltd., fund managed by Armistice Capital LLC and others in a reverse merger transaction.

New major risk - Shareholder dilution

Hepion Pharmaceuticals Receives Non-Compliance Letter from Nasdaq Regarding Stockholder's Deficit

New major risk - Financial position

Hepion Pharmaceuticals Receives Non-Compliance Letter Regarding Nasdaq Listing Rule 5550(a)(2)

High number of new and inexperienced directors

Pharma Two B Ltd. agreed to acquire Hepion Pharmaceuticals, Inc. (NasdaqCM:HEPA) in a reverse merger transaction valued at an implied equity value of approximately $58.5 million.

Hepion Pharmaceuticals, Inc. announced delayed 10-Q filing

Hepion Pharmaceuticals, Inc. Initiates Wind-Down Activities in Phase 2b ‘ASCEND-NASH’ Trial

Hepion Pharmaceuticals, Inc. announced delayed annual 10-K filing

Hepion Pharmaceuticals, Inc. Appoints Michael Purcell to Its Board of Directors

New major risk - Share price stability

Price target decreased by 27% to US$30.00

High number of new and inexperienced directors

Hepion Pharmaceuticals, Inc. Announces Resignation of Anand Reddi from the Board of Directors

Hepion Pharmaceuticals, Inc. Announces CEO Changes

Hepion Pharmaceuticals, Inc. announced delayed 10-Q filing

Hepion Pharmaceuticals Announces Major Reductions in Liver Stiffness with Rencofilstat Treatment in 17-Week Phase 2 Study of Advanced (F3) Mash Liver Disease

New minor risk - Share price stability

Hepion Pharmaceuticals, Inc. Announces the Publication of New Research Study in Mice

New minor risk - Shareholder dilution

Hepion Pharmaceuticals, Inc. announced that it has received $5.000004 million in funding

Price target decreased by 46% to US$23.67

Hepion Pharmaceuticals, Inc. Announces Results from A Study with in Which the Anti-Cancer Activity of Hepion's Lead Drug Candidate, Rencofilstat

Hepion Pharmaceuticals, Inc. Announces Positive Results from Translational Research Study

Hepion Pharmaceuticals, Inc. Announces Resignation of Dr. Todd Hobbs, as the Chief Medical Officer, Effective September 29, 2023

New major risk - Financial position

Hepion Pharmaceuticals (NASDAQ:HEPA) Will Have To Spend Its Cash Wisely

New major risk - Financial position

Hepion Pharmaceuticals Announces Passing of Key Safety Milestone in Phase 2b ‘ASCEND-NASH’ Trial of Rencofilstat

Hepion Pharmaceuticals, Inc. Announces Positive Topline Results from Its Recently Completed Phase 2 Altitude-Nash Clinical Trial

Price target decreased by 10% to US$62.67

High number of new directors

We're Keeping An Eye On Hepion Pharmaceuticals' (NASDAQ:HEPA) Cash Burn Rate

Hepion Pharmaceuticals, Inc. Announces Positive Results of Preclinical Studies Examining Rencofilstat as A Potential Therapeutic for Multiple Myeloma

Hepion Pharmaceuticals, Inc. Presents of Preclinical Study Highlighting Anti-Cancer Activity of Rencofilstat in Combination with Proteosome Inhibitors

Hepion Pharmaceuticals Receives 180-Day Extension by Nasdaq to Meet the Minimum Bid Price Requirements

Hepion Pharmaceuticals Announces Early Completion of Enrollment in Phase 2 'Altitude-Nash' Liver Function Trial

Price target decreased to US$2.50

Hepion Pharmaceuticals, Inc. Announces Publication of Phase 2A 'Ambition' Clinical Trial Results

We're Keeping An Eye On Hepion Pharmaceuticals' (NASDAQ:HEPA) Cash Burn Rate

Hepion Pharmaceuticals, Inc. Announces Initiation of Dosing in Phase 2 'ALTITUDE-NASH' Liver Function Trial

Hepion Pharmaceuticals, Inc. Announces Initiation of Phase 2b ‘ASCEND-NASH’ Trial

Hepion Pharma rises as company begins NASH treatment trial

Hepion Pharmaceuticals, Inc., Annual General Meeting, Aug 05, 2022

Will Hepion Pharmaceuticals (NASDAQ:HEPA) Spend Its Cash Wisely?

Price target decreased to US$4.75

Hepion Pharmaceuticals, Inc. Announces Board Changes

Hepion Pharmaceuticals, Inc. Appoints Dr. Launa J. Aspeslet as Chief Operating Officer

Hepion Pharmaceuticals Receives Notice of Delisting or Failure to Satisfy Continued Listing Rule or Standard from Nasdaq

Hepion Pharmaceuticals Announces Clinical Collaboration with HepQuant in Phase 2b NASH Trial

Hepion Pharmaceuticals, Inc., Annual General Meeting, Jun 24, 2022

Hepion Pharmaceuticals, Inc. announced delayed annual 10-K filing

Hepion Pharmaceuticals CEO Robert Foster - Dash To Beat NASH

Hepion Pharmaceuticals Appoints Eddie C. Cheung to Lead the Company’s Strategic Medical Affairs in Asia

Hepion Pharmaceuticals: Facing The Momentous Year 2022

Hepion Pharmaceuticals Announces FDA Clearance of IND Application for CRV431 in the Treatment of Liver Cancer

Additional Phase IIa Data Confirms Hepion's CRV431 As A Very Promising NASH Candidate Drug

Hepion Pharmaceuticals, Inc Announces Additional Efficacy Data from Its Phase 2A Ambition Clinical Trial

Companies Like Hepion Pharmaceuticals (NASDAQ:HEPA) Are In A Position To Invest In Growth

Hepion Pharmaceuticals: A Promising Early-Stage Biopharma In The NASH Race

Hepion Pharmaceuticals, Inc. Announces Positive Topline Data from Phase 2A ‘Ambition’ Nash Trial and Achieve All Primary Endpoints

Treating Chronic Liver Disease - Interview With Hepion Pharmaceuticals CEO Dr. Robert Foster (Video)

Hepion Pharmaceuticals Completes Final Patient Recruitment in Phase 2A 'AMBITION' Clinical Trial of CRV431 for the Treatment of Advanced NASH

Hepion Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $88.4 million.

What Type Of Shareholders Make Up Hepion Pharmaceuticals, Inc.'s (NASDAQ:HEPA) Share Registry?

Todd M. Hobbs, Joins Hepion Pharmaceuticals as Chief Medical Officer